GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » EPS without NRI

Longeveron (Longeveron) EPS without NRI : $-10.19 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Longeveron EPS without NRI?

Longeveron's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-2.49. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.19.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -66.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -32.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Longeveron's EPS without NRI or its related term are showing as below:

LGVN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.5   Med: -53.1   Max: -31.8
Current: -66.5

During the past 6 years, Longeveron's highest 3-Year average Earnings Per Share (NRI) Growth Rate was -31.80% per year. The lowest was -66.50% per year. And the median was -53.10% per year.

LGVN's 3-Year EPS without NRI Growth Rate is ranked worse than
94.47% of 1302 companies
in the Biotechnology industry
Industry Median: 5.3 vs LGVN: -66.50

Longeveron's EPS (Diluted) for the three months ended in Dec. 2023 was $-2.50. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.20.

Longeveron's EPS (Basic) for the three months ended in Dec. 2023 was $-2.50. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.20.


Longeveron EPS without NRI Historical Data

The historical data trend for Longeveron's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longeveron EPS without NRI Chart

Longeveron Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial -2.32 -2.21 -9.16 -8.33 -10.19

Longeveron Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.10 -2.20 -2.70 -2.80 -2.49

Competitive Comparison of Longeveron's EPS without NRI

For the Biotechnology subindustry, Longeveron's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longeveron's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Longeveron's PE Ratio without NRI falls into.



Longeveron EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Longeveron  (NAS:LGVN) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Longeveron EPS without NRI Related Terms

Thank you for viewing the detailed overview of Longeveron's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Longeveron (Longeveron) Business Description

Traded in Other Exchanges
N/A
Address
1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.
Executives
Cathy Ross director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Jeffrey Pfeffer director
Lisa Locklear officer: Chief Financial Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova officer: Chief Medical Officer 1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo officer: CFO and Treasurer 1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Hashad Mohamed Wa'el Ahmed officer: Chief Executive Officer SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare director, officer: Chief Scientific Officer C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Kwan-hong Christopher Min officer: Chief Medical Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green officer: CEO 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr officer: General Counsel, Secretary 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer director, 10 percent owner 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136

Longeveron (Longeveron) Headlines